Literature DB >> 10639344

Immunization with the Candida albicans membrane fraction and in combination with fluconazole protects against systemic fungal infections.

S Mizutani1, M Endo, T Ino-Ue, M Kurasawa, Y Uno, H Saito, I Kato, K Takesako.   

Abstract

We studied the immunogenicity of a membrane fraction prepared from Candida albicans cells called C. albicans membrane antigen (CMA). The present study revealed that CMA immunization has antifungal activity in mouse models of systemic fungal infection. Immunization of mice by subcutaneous injections of CMA with incomplete Freund adjuvant induced resistance to infections caused not only by C. albicans but also by Aspergillus fumigatus. The level of resistance to candidiasis was as high as that induced by whole-cell immunization. The acquired resistance to candidiasis in the mice immunized with CMA was not diminished by immunosuppressive treatment with cyclophosphamide. The level of resistance to fungal infections was superior to that given by fluconazole (FLC) treatment alone and highly enhanced by the combination with FLC. When CD4(+) cells in CMA-immunized mice were depleted by a monoclonal antibody, the antifungal activity induced by the combination of CMA and FLC was significantly reduced. These results indicate that immunization with CMA is useful for preventing systemic fungal infections and in combination with FLC for increasing resistance after infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10639344      PMCID: PMC89665          DOI: 10.1128/AAC.44.2.243-247.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Induction of protective Th1 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist.

Authors:  E Cenci; A Mencacci; G Del Sero; F Bistoni; L Romani
Journal:  J Infect Dis       Date:  1997-07       Impact factor: 5.226

2.  Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus.

Authors:  T C White
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

3.  Effect of granulocyte colony-stimulating factor on the candidacidal activity of polymorphonuclear neutrophils and their collaboration with fluconazole.

Authors:  U Natarajan; E Brummer; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

4.  A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice.

Authors:  A Mencacci; A Torosantucci; R Spaccapelo; L Romani; F Bistoni; A Cassone
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

5.  Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.

Authors:  D Sanglard; K Kuchler; F Ischer; J L Pagani; M Monod; J Bille
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

6.  Increased sensitivity of Candida albicans cells accumulating 14 alpha-methylated sterols to active oxygen: possible relevance to in vivo efficacies of azole antifungal agents.

Authors:  O Shimokawa; H Nakayama
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

7.  Candidacidal activity of macrophages from immunocompetent and congenitally immunodeficient mice.

Authors:  A Vazquez-Torres; J Jones-Carson; E Balish
Journal:  J Infect Dis       Date:  1994-07       Impact factor: 5.226

8.  The Candida albicans phospholipomannan induces in vitro production of tumour necrosis factor-alpha from human and murine macrophages.

Authors:  T Jouault; A Bernigaud; G Lepage; P A Trinel; D Poulain
Journal:  Immunology       Date:  1994-10       Impact factor: 7.397

9.  Effects of recombinant human granulocyte-colony stimulating factor on neutropenic mice infected with Candida albicans: acceleration of recovery from neutropenia and potentiation of anti-C. albicans resistance.

Authors:  M Hamood; P F Bluche; C De Vroey; F Corazza; W Bujan; P Fondu
Journal:  Mycoses       Date:  1994 Mar-Apr       Impact factor: 4.377

10.  Antibody response that protects against disseminated candidiasis.

Authors:  Y Han; J E Cutler
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

View more
  1 in total

1.  Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90.

Authors:  Ruth C Matthews; Gordon Rigg; Samantha Hodgetts; Tracey Carter; Caroline Chapman; Carl Gregory; Chris Illidge; James Burnie
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.